GlassScriptPhysician profile
Mary J Kemp
NPI 1356567689
$8,031.64
in general payments reported to CMS, 2019-2025
48 companies · $2,267 in 2025
The $2,267 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $1,502 · 2023: $2,079 · 2024: $2,066 · 2025: $2,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,412.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,115.37 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,037.67 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Insulet Corporation | $594.09 | 2022-2025 | Omnipod |
| Abbott Laboratories | $531.34 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $398.98 | 2022-2025 | Evenity, Tepezza, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.58 | 2022-2025 | Jardiance, Synjardy |
| Xeris Pharmaceuticals, INC. | $303.39 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Radius Health, INC. | $301.54 | 2023-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $287.38 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $251.93 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $244.17 | 2021-2024 | Farxiga |
| Cequr Corporation | $193.73 | 2023-2025 | Cequr Simplicity |
| Ibsa Pharma INC. | $193.19 | 2022-2025 | Tirosint, Tirosint, Licart |
| Lifescan, INC. | $174.14 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.38 | 2022-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $150.14 | 2022-2025 | Isturisa, Signifor Lar |
| Pfizer INC. | $143.86 | 2022-2025 | |
| Antares Pharma, INC. | $143.70 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Amneal Pharmaceuticals LLC | $139.52 | 2021-2025 | Unithroid |
| Dexcom, INC. | $119.47 | 2023-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $96.15 | 2022-2024 | |
| Mannkind Corporation | $89.44 | 2024-2025 | |
| Kyowa Kirin, INC. | $79.74 | 2023-2024 | Crysvita |
| Ascendis Pharma Endocrinology INC | $74.73 | 2023-2025 | Yorvipath |
| Esperion Therapeutics, INC. | $69.78 | 2022-2025 | Nexletol |
| Alexion Pharmaceuticals, INC. | $69.68 | 2024 | Strensiq |
| Averitas Pharma INC. | $68.33 | 2025 | Qutenza |
| Sequel Med Tech, LLC | $64.80 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $54.61 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Horizon Therapeutics Plc | $50.92 | 2022 | |
| Genentech USA, INC. | $46.33 | 2024 | Xolair |
| Tolmar, INC. | $46.09 | 2024-2025 | Jatenzo |
| Corcept Therapeutics | $41.18 | 2024 | Korlym |
| Beta Bionics, INC. | $36.42 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Merck Sharp & Dohme LLC | $33.89 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.80 | 2022 | |
| Verity Pharmaceuticals INC. | $26.83 | 2024 | Tlando |
| Madrigal Pharmaceuticals | $25.16 | 2025 | Rezdiffra |
| Neurocrine Biosciences, INC. | $22.05 | 2025 | |
| Amarin Pharma, INC. | $21.42 | 2022 | |
| Soleno Therapeutics, INC. | $20.98 | 2025 | Vykat Xr |
| Nevro Corp. | $20.62 | 2023 | Senza |
| Ultragenyx Pharmaceutical INC. | $20.50 | 2022 | |
| Astellas Pharma US INC | $18.69 | 2023 | Veozah |
| Eusa Pharma (US) LLC | $17.92 | 2022 | |
| Medtronic, INC. | $17.88 | 2022 | |
| Boston Scientific Corporation | $14.38 | 2025 | General - Pain Management |
| Clarus Therapeutics INC. | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Kemp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.